EP2416650A4 - NANOPARTICLE FORMULATIONS AND USES THEREOF - Google Patents
NANOPARTICLE FORMULATIONS AND USES THEREOFInfo
- Publication number
- EP2416650A4 EP2416650A4 EP10762524.6A EP10762524A EP2416650A4 EP 2416650 A4 EP2416650 A4 EP 2416650A4 EP 10762524 A EP10762524 A EP 10762524A EP 2416650 A4 EP2416650 A4 EP 2416650A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- nanoparticle formulations
- nanoparticle
- formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16854009P | 2009-04-10 | 2009-04-10 | |
| PCT/US2010/030596 WO2010118365A1 (en) | 2009-04-10 | 2010-04-09 | Nanoparticle formulations and uses therof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP2416650A1 EP2416650A1 (en) | 2012-02-15 |
| EP2416650A4 true EP2416650A4 (en) | 2014-01-01 |
| EP2416650B1 EP2416650B1 (en) | 2020-02-26 |
Family
ID=42936607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP10762524.6A Active EP2416650B1 (en) | 2009-04-10 | 2010-04-09 | Nanoparticle formulations and uses therof |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20130195983A1 (en) |
| EP (1) | EP2416650B1 (en) |
| JP (2) | JP2012523433A (en) |
| KR (1) | KR20120005505A (en) |
| CN (1) | CN102458112A (en) |
| AU (2) | AU2010233097B2 (en) |
| BR (1) | BRPI1014160A2 (en) |
| CA (1) | CA2758200A1 (en) |
| ES (1) | ES2788298T3 (en) |
| IL (1) | IL215665A0 (en) |
| MX (1) | MX2011010673A (en) |
| WO (1) | WO2010118365A1 (en) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| CN103405405A (en) | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | Compositions and methods of delivery of pharmacological agents |
| US8916546B2 (en) | 2003-08-29 | 2014-12-23 | Therapeutic Research Llc | Materials and methods for treatment and diagnosis of disorders associated with oxidative stress |
| SI1853250T1 (en) | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| KR101420445B1 (en) * | 2005-08-31 | 2014-07-16 | 아브락시스 바이오사이언스, 엘엘씨 | Composition comprising water-insoluble pharmaceutical agent and antimicrobial agent |
| EP3470071A1 (en) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| WO2008109163A1 (en) * | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc. | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| JP5579057B2 (en) * | 2007-06-01 | 2014-08-27 | アブラクシス バイオサイエンス， エルエルシー | Methods and compositions for the treatment of recurrent cancer |
| HRP20192259T1 (en) | 2009-04-15 | 2020-03-06 | Abraxis Bioscience, Llc | PREPARATIONS OF NON-PARTICLES WITHOUT PRION AND METHODS OF THEIR PRODUCTION |
| CA3051495A1 (en) | 2010-03-26 | 2011-09-29 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
| NZ717490A (en) | 2010-03-29 | 2017-12-22 | Abraxis Bioscience Llc | Methods of treating cancer |
| KR20130028727A (en) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| BR112012030909A2 (en) | 2010-06-04 | 2020-08-18 | Abraxis Bioscience, Llc | pancreatic cancer treatment methods |
| JP6038123B2 (en) | 2011-04-28 | 2016-12-07 | アブラクシス バイオサイエンス， エルエルシー | Intravascular delivery of nanoparticle compositions and their use |
| PT2707030T (en) | 2011-05-09 | 2020-05-22 | Mayo Found Medical Education & Res | Cancer treatments |
| JP6216721B2 (en) | 2011-12-14 | 2017-10-18 | アブラクシス バイオサイエンス， エルエルシー | Use of polymeric excipients to lyophilize or freeze particles |
| US10413606B2 (en) | 2012-10-01 | 2019-09-17 | Mayo Foundation For Medical Education And Research | Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| WO2014074995A1 (en) * | 2012-11-09 | 2014-05-15 | Scidose, Llc | Enema composition for treatment of ulcerative colitis having long term stability |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| EP2968191B1 (en) | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| US20160346389A1 (en) * | 2013-09-12 | 2016-12-01 | Albert Einstein College Of Medicine Inc. | Modified paramagnetic nanoparticles for targeted delivery of therapeutics and methods thereof |
| KR101534929B1 (en) | 2013-10-17 | 2015-07-07 | 현대자동차주식회사 | Multi parts autotransferring apparatus for vehicle |
| US20160250351A1 (en) | 2014-06-13 | 2016-09-01 | Mayo Foundation For Medical Education And Research | Treating Lymphomas |
| EP3834889A1 (en) | 2014-06-16 | 2021-06-16 | Mayo Foundation for Medical Education and Research | Treating myelomas |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| CN104306339A (en) * | 2014-10-22 | 2015-01-28 | 南京大学 | Thymidylate synthase preparation loaded albumin nano-microsphere and preparation method thereof |
| CN105727303B (en) * | 2014-12-12 | 2019-06-28 | 四川科伦药物研究院有限公司 | A kind of high albumin composition for carrying Cabazitaxel drug and its preparation and preparation method |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| PL3998069T3 (en) | 2015-06-29 | 2025-03-31 | Abraxis Bioscience, Llc | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| TW201707725A (en) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | Carrier-antibody compositions and methods of making and using the same |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| WO2017097974A1 (en) * | 2015-12-10 | 2017-06-15 | Dsm Ip Assets B.V. | Vitamin formulation |
| WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
| CN109069420A (en) | 2016-01-11 | 2018-12-21 | 埃皮辛特瑞柯斯公司 | Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone |
| WO2017139698A1 (en) | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| US11305020B2 (en) | 2016-03-21 | 2022-04-19 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| EP3432928A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | METHODS FOR ENHANCING THE THERAPEUTIC INDEX OF A CHEMOTHERAPEUTIC MEDICAMENT |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| CN109890419A (en) | 2016-09-01 | 2019-06-14 | 梅约医学教育与研究基金会 | Carrier-PD-L1 binding agent composition for treating cancer |
| CA3035377A1 (en) | 2016-09-01 | 2018-03-08 | Mayo Foundation For Medical Education And Research | Nanoparticle compositions for targeting t-cell cancers |
| EP3509643A1 (en) * | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| WO2018048816A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Methods of treating pd-l1 expressing cancer |
| WO2018195416A1 (en) | 2017-04-21 | 2018-10-25 | Mayo Foundation For Medical Education And Research | Polypeptide-antibody complexes and uses thereof |
| EP3648740A1 (en) * | 2017-07-07 | 2020-05-13 | EpicentRx, Inc. | Compositions for parenteral administration of therapeutic agents |
| WO2019164593A2 (en) | 2018-01-08 | 2019-08-29 | Epicentrx, Inc. | Methods and compositions utilizing rrx-001 combination therapy for radioprotection |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| CN112789057A (en) * | 2018-07-24 | 2021-05-11 | 詹纽瑞治疗公司 | Nanoparticle compositions |
| JP7832108B2 (en) | 2019-10-28 | 2026-03-17 | アブラクシス バイオサイエンス， エルエルシー | Pharmaceutical composition of albumin and rapamycin |
| EP4054550A4 (en) * | 2019-11-05 | 2024-01-17 | Luminus Biosciences Inc. | Nanoparticles comprising prodrugs stabilized by albumin for treatment of cancer and other diseases |
| JP2021093979A (en) * | 2019-12-18 | 2021-06-24 | 太陽化学株式会社 | Poorly water-soluble substance-containing composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749868B1 (en) * | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| WO2006089207A2 (en) * | 2005-02-18 | 2006-08-24 | Abraxis Bioscience, Inc. | Drugs with improved hydrophobicity for incorporation in medical devices |
| US20070082838A1 (en) * | 2005-08-31 | 2007-04-12 | Abraxis Bioscience, Inc. | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5558071A (en) * | 1994-03-07 | 1996-09-24 | Combustion Electromagnetics, Inc. | Ignition system power converter and controller |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| US20070092563A1 (en) | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| BRPI9810945B8 (en) * | 1997-06-27 | 2021-05-25 | Abraxis Bioscience Inc | formulations of pharmacological agents, methods for their preparation and methods for using them |
| IL134830A0 (en) * | 2000-03-01 | 2001-05-20 | Chay 13 Medical Res Group N V | Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them |
| MXPA02009031A (en) * | 2000-03-14 | 2004-08-19 | Amylin Pharmaceuticals Inc | Effects of glucagon like peptide 1 (7 36) on antro pyloro duodenal motility. |
| CN1925874B (en) * | 2002-12-09 | 2014-12-17 | 阿布拉西斯生物科学有限责任公司 | Compositions and methods of delivering agents |
| CN103405405A (en) * | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | Compositions and methods of delivery of pharmacological agents |
| BRPI0717171B1 (en) * | 2006-09-25 | 2023-10-17 | Archer Daniels Midland Company | SUPERABSORBENT MATERIAL |
| US20130084243A1 (en) * | 2010-01-27 | 2013-04-04 | Liliane Goetsch | Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
| EP2326306A1 (en) * | 2008-09-25 | 2011-06-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
| US20110028412A1 (en) * | 2009-08-03 | 2011-02-03 | Cappellos, Inc. | Herbal enhanced analgesic formulations |
-
2010
- 2010-04-09 EP EP10762524.6A patent/EP2416650B1/en active Active
- 2010-04-09 KR KR1020117026658A patent/KR20120005505A/en not_active Ceased
- 2010-04-09 BR BRPI1014160-0A patent/BRPI1014160A2/en not_active IP Right Cessation
- 2010-04-09 US US13/263,723 patent/US20130195983A1/en not_active Abandoned
- 2010-04-09 CA CA2758200A patent/CA2758200A1/en not_active Abandoned
- 2010-04-09 JP JP2012504898A patent/JP2012523433A/en active Pending
- 2010-04-09 ES ES10762524T patent/ES2788298T3/en active Active
- 2010-04-09 AU AU2010233097A patent/AU2010233097B2/en active Active
- 2010-04-09 CN CN2010800259726A patent/CN102458112A/en active Pending
- 2010-04-09 MX MX2011010673A patent/MX2011010673A/en not_active Application Discontinuation
- 2010-04-09 WO PCT/US2010/030596 patent/WO2010118365A1/en not_active Ceased
-
2011
- 2011-10-10 IL IL215665A patent/IL215665A0/en unknown
-
2013
- 2013-02-28 US US13/781,479 patent/US20140080901A1/en not_active Abandoned
-
2016
- 2016-07-07 AU AU2016204693A patent/AU2016204693A1/en not_active Abandoned
- 2016-11-29 US US15/364,189 patent/US20170172975A1/en not_active Abandoned
-
2017
- 2017-03-29 JP JP2017065384A patent/JP2017114913A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749868B1 (en) * | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| WO2006089207A2 (en) * | 2005-02-18 | 2006-08-24 | Abraxis Bioscience, Inc. | Drugs with improved hydrophobicity for incorporation in medical devices |
| US20070082838A1 (en) * | 2005-08-31 | 2007-04-12 | Abraxis Bioscience, Inc. | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
Non-Patent Citations (3)
| Title |
|---|
| F. D. KOLODGIE: "Sustained Reduction of In-Stent Neointimal Growth With the Use of a Novel Systemic Nanoparticle Paclitaxel", CIRCULATION, vol. 106, no. 10, 19 August 2002 (2002-08-19), pages 1195 - 1198, XP055089573, ISSN: 0009-7322, DOI: 10.1161/01.CIR.0000032141.31476.15 * |
| See also references of WO2010118365A1 * |
| W. J. GRADISHAR: "Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil-Based Paclitaxel in Women With Breast Cancer", JOURNAL OF CLINICAL ONCOLOGY, vol. 23, no. 31, November 2005 (2005-11-01), pages 7794 - 7803, XP055089298, ISSN: 0732-183X, DOI: 10.1200/JCO.2005.04.937 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010118365A1 (en) | 2010-10-14 |
| KR20120005505A (en) | 2012-01-16 |
| IL215665A0 (en) | 2012-01-31 |
| JP2012523433A (en) | 2012-10-04 |
| US20170172975A1 (en) | 2017-06-22 |
| BRPI1014160A2 (en) | 2015-08-25 |
| AU2010233097A1 (en) | 2011-11-24 |
| US20130195983A1 (en) | 2013-08-01 |
| CN102458112A (en) | 2012-05-16 |
| EP2416650A1 (en) | 2012-02-15 |
| AU2016204693A1 (en) | 2016-07-28 |
| JP2017114913A (en) | 2017-06-29 |
| MX2011010673A (en) | 2012-02-21 |
| EP2416650B1 (en) | 2020-02-26 |
| AU2010233097B2 (en) | 2016-04-07 |
| CA2758200A1 (en) | 2010-10-14 |
| US20140080901A1 (en) | 2014-03-20 |
| ES2788298T3 (en) | 2020-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2416650A4 (en) | NANOPARTICLE FORMULATIONS AND USES THEREOF | |
| FR25C1008I2 (en) | Immunoconjugates against folate receptor 1 and their uses | |
| EP2542221A4 (en) | PROTEIN CONCENTRATED FORMULATIONS AND USES THEREOF | |
| FR17C1059I2 (en) | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | |
| EP2504439A4 (en) | OPTIMIZED ENDONUCLEASES AND USES THEREOF | |
| EP2365962A4 (en) | LIPIDOIDS AMINOALCOOL AND USES THEREOF | |
| EP2419732A4 (en) | PRION-FREE NANOPARTICLE COMPOSITIONS AND METHODS RELATED THERETO | |
| ZA201008045B (en) | Nanoparticle formulations and uses thereof | |
| EP2593463A4 (en) | RIFAXIMINE FORMULATIONS AND CORRESPONDING USES THEREOF | |
| EP2701731A4 (en) | INTRAVASCULAR ADMINISTRATION OF NANOPARTICLE COMPOSITIONS AND USES THEREOF | |
| EP2475717A4 (en) | PARTICLES COMPRISING NANOPARTICLES, USES THEREOF, AND METHODS | |
| EP2874616A4 (en) | TOPICAL DISINFECTION FORMULATIONS AND USES THEREOF | |
| EP2235175A4 (en) | POLYPEPTIDE-NUCLEIC ACID CONJUGATES AND USES THEREOF | |
| EP2454367A4 (en) | CUSTOM COLLAGENES AND THEIR USES | |
| EP2279210A4 (en) | LYSOSOMIAL TARGETING PEPTIDES AND USES THEREOF | |
| EP2197894A4 (en) | DEGENATED OLIGONUCLEOTIDES AND USES THEREOF | |
| EP2885318A4 (en) | PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF | |
| EP2646446A4 (en) | BROMODOMAIN INHIBITORS AND USES THEREOF | |
| EP2426110A4 (en) | PYRAZOLYLACRYLONITRILE COMPOUNDS AND USES THEREOF | |
| EP2158221A4 (en) | COVALENT DI-ANTIBODIES AND USES THEREOF | |
| EP2542089A4 (en) | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | |
| EP2405886A4 (en) | TOPICAL PERSONAL AND PHARMACEUTICAL CARE COMPOSITIONS AND USES THEREOF | |
| EP2654422A4 (en) | BICYCLO [3.2.1] OCTYLAMIDE DERIVATIVES AND USES THEREOF | |
| EP2401264A4 (en) | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | |
| EP2605789A4 (en) | MODIFIED RELAXINE POLYPEPTIDES AND USES THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20111108 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA ME RS |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20131129 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/51 20060101ALI20131125BHEP Ipc: A61K 31/337 20060101AFI20131125BHEP Ipc: A61K 9/14 20060101ALI20131125BHEP |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ABRAXIS BIOSCIENCE, LLC |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20180615 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20190918 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: TRIEU, VUONG Inventor name: DESAI, NEIL P. Inventor name: TAO, CHUNLIN Inventor name: DE, TAPAS Inventor name: CI, SHERRY XIAOPEI |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: CI, SHERRY XIAOPEI Inventor name: DESAI, NEIL P. Inventor name: TRIEU, VUONG Inventor name: TAO, CHUNLIN Inventor name: DE, TAPAS |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA ME RS |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602010063238 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1236799 Country of ref document: AT Kind code of ref document: T Effective date: 20200315 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200526 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20200226 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200527 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200626 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200526 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2788298 Country of ref document: ES Kind code of ref document: T3 Effective date: 20201021 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200719 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1236799 Country of ref document: AT Kind code of ref document: T Effective date: 20200226 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602010063238 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200430 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200430 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200409 |
|
| 26N | No opposition filed |
Effective date: 20201127 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20200430 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200430 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200409 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200226 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230516 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20250305 Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20250506 Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20260219 Year of fee payment: 17 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20260320 Year of fee payment: 17 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20260309 Year of fee payment: 17 |